Synergistic Activation of Innate and Adaptive Immune Responses

You are reading version 1 of this direction, frozen 2026-10-04. The latest version is version 2.

Version 1 of 229 papers44 conceptsfrozen 2026-10-04

Traditional immunotherapy has largely focused on the adaptive immune system, specifically by "releasing the brakes" on T-cells. However, clinical experience has shown that blocking a single inhibitory pathway is often insufficient. Tumors employ a multi-layered defense that suppresses both the immediate, innate response of macrophages and natural killer (NK) cells and the long-term, adaptive response of T-cells.

A growing body of research suggests that the most effective way to overcome this resistance is to bridge these two systems, simultaneously removing inhibitory signals while providing active stimulatory "accelerators."

The Brake and Accelerator Model

The fundamental intuition behind this research direction is that immune cells in the tumor microenvironment are not just ignored; they are actively suppressed. As Jing Gao and colleagues argue in their work on ES038, simply removing a "brake" (an inhibitory receptor) often fails to trigger a response because the cell lacks the necessary "gas" (a stimulatory signal) to move.

Their approach involves a dual-action mechanism: blocking the inhibitory NKG2A receptor while simultaneously engaging the stimulatory NKG2C receptor on NK cells. This "flips" the functional state of the cell from inhibited to active. Similarly, Fei Gu demonstrated that combining PD-1 blockade with IL12 cytokine signaling can reverse immune exhaustion by providing the necessary secondary signals to drive a robust anti-tumor response Gu et al. (2025).

Bridging Innate and Adaptive Checkpoints

The most prominent application of this synergy is the simultaneous targeting of the CD47/SIRPα "don't eat me" signal (innate) and the PD-1/PD-L1 "don't kill me" signal (adaptive).

Dawei Sun and Jiahui Hu developed ES019, a bispecific antibody that bridges these pathways. The logic is circular and reinforcing: blocking SIRPα allows macrophages to engulf tumor cells, and these macrophages then act as antigen-presenting cells (APCs) to further prime the T-cells that have been released by the PD-L1 blockade. Shengzhe Jin confirmed this synergy using a small-molecule approach, showing that dual inhibition restores macrophage phagocytosis while preventing T-cell exhaustion Jin et al. (2024).

Solving the Toxicity Problem via Affinity Mismatch

One major hurdle in targeting innate checkpoints like CD47 is systemic toxicity; because CD47 is expressed on healthy red blood cells, many early drugs caused severe anemia. Hang Ke and Xiaoyu An pioneered a solution called "affinity mismatch" in their work on HX009.

By engineering the bispecific antibody to have a high affinity for PD-1 but a deliberately weakened affinity for CD47, the drug preferentially anchors to T-cells in the tumor microenvironment. Only after it is "tethered" to the tumor site does it engage the CD47 signal, thereby sparing healthy blood cells in circulation while maintaining potent anti-tumor activity Ke et al. (2023).

APCs as the Gatekeepers of Immunity

While T-cells are the "soldiers," researchers like Cassia Wang emphasize that antigen-presenting cells (APCs) are the "gatekeepers." If dendritic cells or macrophages are suppressed, the adaptive immune system never receives the orders to attack.

Andreas Saltos and Hong Zheng demonstrated this by using an oncolytic virus, MEM-288, to deliver IFNβ and CD40 signals directly into tumors. This dual-pathway stimulation forces the maturation and migration of dendritic cells to the lymph nodes, effectively "turning the tumor into its own vaccine factory." This highlights that the innate system's role isn't just direct killing—it is the essential precursor to a sustained adaptive response.

Expanding the Target Space

The strategy of dual-action modulation is now expanding beyond standard protein checkpoints:

  • Glycan Blockade: Jessica C. Stark developed "AbLecs" to strip away the "sugar shield" (glycans) that tumors use to hide from the immune system, combining this with traditional checkpoint blockade Stark et al. (2025).
  • Triple Targeting: Ming Yi has pushed the boundaries further by simultaneously inhibiting PD-L1 and TGF-β while adding a STING agonist to trigger innate sensing, creating a three-pronged attack on the tumor microenvironment Yi et al. (2026).

By treating the immune system as an integrated circuit rather than a collection of isolated pathways, these researchers are developing therapies that are not just more potent, but more resilient to the diverse ways tumors attempt to evade detection.

Papers in this version

History & citationVersion 2 · 2026-10-04

Current · Permanent link

  1. Version 2 (latest) · 2026-10-04 · 23 papers
  2. Version 1 · 2026-10-04 · 29 papers
Cite this direction

Latest version (a living page):

@misc{lacuna_dual_immune_checkpoint_inhibition_c9193b46,
  title = {dual immune checkpoint inhibition},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/dual-immune-checkpoint-inhibition/rdr_c9193b4629d7465581e2d32eaeea3dbc},
  note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-20},
}

This exact version (version 1, frozen text):

@misc{lacuna_synergistic_activation_of_innate_and_ada_c9193b46_v1,
  title = {Synergistic Activation of Innate and Adaptive Immune Responses},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/synergistic-activation-of-innate-and-adaptive-immune-responses/rdr_c9193b4629d7465581e2d32eaeea3dbc/v/1},
  note = {Version 1, frozen 2026-10-04. Accessed 2026-11-20},
}